GATA binding protein 3 (GATA3) (GATA3)

GATA binding protein 3 (GATA3) is a critical zinc-finger transcription factor that serves as the master regulator for the differentiation and maintenance of T helper type 2 (Th2) cells [UniProt: P23771]. It functions by directly binding to the promoters of Th2 cytokine genes, including IL-4, IL-5, and IL-13, while simultaneously inhibiting the development of Th1 cells [PubMed: 25981970]. In clinical contexts, GATA3 is highly associated with allergic inflammatory diseases such as asthma and atopic dermatitis, where its overexpression drives chronic airway inflammation and eosinophilia [NCBI Gene: 2625]. Beyond the immune system, GATA3 is essential for the development of the mammary glands, kidneys, and inner ear, and it is frequently used as a diagnostic marker in breast and urothelial cancers [PubMed: 24633671]. Therapeutic strategies targeting GATA3 have primarily utilized DNAzyme technology, such as the drug candidate SB010, which specifically cleaves GATA3 mRNA to reduce protein levels and dampen the Th2-driven inflammatory response [PubMed: 25981970]. Due to its broad physiological roles, drug development focuses on localized delivery to minimize potential systemic side effects in non-target tissues.

Other names

GATA-binding factor 3HDRHDRSGATA3

DNAzyme-mediated cleavage of GATA3 mRNA to inhibit protein translation and subsequent Th2 cytokine production [PubMed: 25981970].